Epidemiology of inflammatory bowel disease in sub-Saharan Africa: A review of the current status

G Watermeyer,1 FCP (SA); D Epstein,2 FCP (SA); O Adegoke,3 FMCPath; C Kassianides,4 FCP (SA); O Ojo,5 FMCPath; M Setshed,1 PhD

1 Division of Gastroenterology, Department of Medicine, Faculty of Health Sciences, Groote Schuur Hospital and University of Cape Town, South Africa
2 Life Vincent Pallotti Hospital, Cape Town, South Africa
3 Department of Pathology, University College Hospital, University of Ibadan, Nigeria
4 Morningside Mediclinic, Johannesburg, South Africa
5 Gastroenterology and Liver Pathology Unit, Obafemi Awolowo University and Teaching Hospital, Ile-Ife, Nigeria

Corresponding author: G Watermeyer (gillian.watermeyer@uct.ac.za)

While inflammatory bowel disease (IBD) has been well characterised in the West and other parts of the world, there are little data from sub-Saharan Africa (SSA). To throw light on the current status of IBD in SSA, we performed a systematic review of the literature, extracting relevant publications. We found only 210 documented IBD cases in SSA (excluding South Africa (SA)), which were reported in 34 publications until August 2019. The majority were cases of ulcerative colitis. Only three reports, all from SA, attempted to determine IBD incidence rates. The rest were mostly case reports or small case series; the largest from Nigeria comprised 32 patients. The paucity of documented cases possibly reflects under-diagnosis and under-reporting. Major deficiencies in diagnostic and clinical capacity were noted, which need to be addressed going forward.


The term inflammatory bowel disease (IBD) mainly refers to two diseases, Crohn's disease (CD) and ulcerative colitis (UC). The aetiology of IBD remains unclear, but possibly reflects an aberrant interaction between T-cell immune responses, the microbiome and environmental triggers in genetically susceptible hosts.1 During the past 100 years, the incidence of IBD appears to have risen and subsequently plateaued in much of the western world. In a recent systematic review, Ng et al.2 provided a global perspective on the epidemiology of IBD in the 21st century. The authors also evaluated temporal trends and found that IBD was highest in the West, with prevalence rates of >0.3% in North America, Oceania and many countries in Europe. However, 73% of studies on CD and 83% of studies on UC reported a stable or decreasing incidence of IBD in these regions.

In sharp contrast, there is a dearth of information on the epidemiology of IBD in SSA and its constituent countries. Since the advent of globalisation, there has been accelerated industrialisation in Asia, the Middle East and South America. The epidemiology of IBD appears to have mirrored this, with a rapid increase reported in areas where IBD has been considered uncommon in the past.2,3 Ng et al.4 have shown that in newly industrialised nations across Asia, North Africa and South America, IBD incidence has increased over time.

Motivated by a need to fill the gap created by the limited information on IBD epidemiology in SSA, we performed a comprehensive review of the current literature on IBD in the countries of the subregion. We also propose strategies to address the diagnostic and clinical deficiencies that the current dearth of information on IBD implies for the subregion.

Methods

An electronic search of the literature of the MEDLINE and Cochrane databases using medical subject headings (MeSH) terms and keywords, such as Crohn’s disease, ulcerative colitis, inflammatory bowel disease, IBD, epidemiology, incidence, prevalence, sub-Saharan Africa, Africa and individual country names, individually or in combination, were employed to identify SSA articles on IBD that were published until August 2019. We also collected journal articles from the references cited by the publications that we had obtained from the initial search of the major databases listed above. The publications thus obtained, formed the main source of materials for this study.

Results

Only 3 studies, all from South Africa (SA), reported on IBD incidence rates.3-5 Over two time periods, 1970 - 1974 and 1975 - 1980, there was a significant increase in reported cases of IBD. Incidence rates for CD among the coloured, white and black population groups were 1.8, 2.6 and 0.3/100 000 per year, respectively, and for UC 1.9, 5.0 and 0.6/100 000 per year, respectively.3,5

Thirty-four additional publications were identified from all over the subregion, excluding SA.6-41 These were mostly case reports or small case series of patients diagnosed and managed in hospitals and clinics where the respective authors worked. Table 1 depicts details of these reports. A total of 210 cases of IBD were reported from SSA, excluding SA.6-41 Notably, of the aforementioned 34 publications, 1 was a single multicentre study.41 In that study, 118 missionaries working in 75 stations or hospitals associated with their missions, which were spread over 24 SSA countries, provided information about their medical practice over a 1-year period. Details were collected of the total number of patients seen during that year, and the number of cases of IBD encountered. Of >1 million outpatients and ~190 000 inpatients who were seen by these doctors, only 22 cases of IBD were found. The authors did not specify the type of IBD seen in individual cases.

In 1998, Ogutu et al.47 from Kenya reported a cross-sectional study describing abnormalities identified at colonoscopy over a 2-year period. Consecutive patients (n=247) underwent endoscopy...
during the study period. The major indications for colonoscopy were lower abdominal pain (35.6%), non-bloody diarrhoea (22.3%), constipation (21.4%) and rectal bleeding (19.8%). Fifty-three percent of patients had abnormal mucosal findings, the most common being proctocolitis (20.2%). A histological diagnosis of nonspecific colitis was made in 28.5% and of UC in 7.3% of patients. There was 1 case of Crohn’s colitis and 5 cases of infective colitis.

Table 1. Analysis of published reports of inflammatory bowel disease in sub-Saharan African countries (excluding South Africa)

<table>
<thead>
<tr>
<th>Country</th>
<th>IBD, n</th>
<th>UC, n</th>
<th>CD, n</th>
<th>Not specified or IBD-U, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burkina Faso</td>
<td>10</td>
<td>8</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Cameroon</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>13</td>
<td>5</td>
<td>8</td>
<td>-</td>
</tr>
<tr>
<td>Ghana</td>
<td>45</td>
<td>24</td>
<td>4</td>
<td>17*</td>
</tr>
<tr>
<td>Ivory Coast</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Kenya</td>
<td>18</td>
<td>18</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Nigeria</td>
<td>63</td>
<td>35</td>
<td>22</td>
<td>6*</td>
</tr>
<tr>
<td>Rwanda</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>-</td>
</tr>
<tr>
<td>Senegal</td>
<td>14</td>
<td>14</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>Togo</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>Tanzania</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>Togo</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>-</td>
</tr>
<tr>
<td>Togo</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>Uganda</td>
<td>4</td>
<td>4</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>7</td>
<td>7</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>SSA countries, n=22</td>
<td>22</td>
<td>-</td>
<td>-</td>
<td>22*</td>
</tr>
</tbody>
</table>

*Not specified.

IBD = inflammatory bowel disease; UC = ulcerative colitis; CD = Crohn’s disease; SSA = sub-Saharan Africa; IBD-U = IBD unclassified.

IBD treatment for UC and CD was non-

Mguti, 1989

Archampong and Nkrumah, 1989

Awori

Kibaya, 1946

Dia et al., 2014

Jones et al., 1977

Agoda-Kouserna et al., 2012

Billinghurst and Welchman, 1966

Mguti, 1989

In a series of 12 patients reported from Nigeria, the majority had UC. All patients presented with bloody diarrhoea. None of the patients had a family history of IBD, and no extra-intestinal manifestations were reported in association with the disease. As with the Ghanaian studies, treatment for UC and CD was non-discriminatory and included 5-aminosalicylate preparations (almost all patients received salazopyrine), antibiotics and corticosteroids. None of the patients was treated with immunomodulators (azathioprine, 6-mercaptopurine or methotrexate) or biologics.

The median delay of IBD treatment was 5 years, which was explained by the finding of entamoeba cysts in the stools of up to a third of patients at initial presentation. Therefore, they were first treated for amoebiasis with metronidazole, with no relief of symptoms. A similar finding was reported in a Senegalese study of 14 patients with UC, where 4 had initially been treated for amoebiasis.

In 2014, Obaseki and Forae from Nigeria reported 32 cases of IBD diagnosed over a 4-year period; 14 of CD, 12 of UC and 6 of IBD – unclassified. Two-thirds of the patients were male. Thirty percent of the patients had isolated colonic CD and 53.9% ileocolonic CD,
while only 1 patient had isolated ileal involvement. In this report, azathioprine had been used as treatment, but none of the patients received biologics.

Discussion

During the past 100 years, the incidence of IBD appears to have risen and subsequently plateaued in much of the western world. A similar trend has recently been noted in many newly industrialised nations across Asia, North Africa and South America. Recently, a preliminary analysis of a large IBD registry of >3 000 SA patients showed an exponential increase in IBD over the past 70 years (David Epstein – personal communication, 2019). IBD now affects members of all ethnic groups, with UC appearing to be more prevalent in black patients, severe penetrating CD affecting an increased number of the Cape coloured community, and a relatively low prevalence of IB among the Indian community (David Epstein – personal communication, 2019).

With the exception of SA, IBD has long been considered uncommon in SSA. However, given the paucity of data describing the epidemiology of IBD in this subregion, the true burden of the disease remains largely unknown. Despite the 46 countries of SSA being home to more than a billion people, <300 cases were identified in this review, excluding SA. The first reported patient was from Rwanda (1946), and 4 cases of UC were described in Uganda in 1966. Subsequently, there have been other, albeit infrequent, case reports or small series from a number of countries in SSA, suggesting the rarity of IBD in the region. A 1989 study of rural mission hospitals in 24 SSA countries identified only 22 IBD cases among 1.19 million patients. Similarly, in Burkina Faso, of the 1,221 colonoscopies performed from 1994 to 1997, only 4 cases of IBD were detected.

During recent years, however, the increasing number of published reports tends to suggest that the incidence of IBD in SSA may be increasing. A single report from Ghana showed a significant rise in the number of IBD patients seen at a single referral centre, with a 65% increase in case finding over 15 years. Additional reports have emerged from Nigeria, as well as other SSA countries, lending further credence to the notion of an apparent rise in incidence. A study from Kenya showed that, among patients referred for colonoscopy who had biopsies performed, 7% had UC and 1 patient had CD. Heightened physician and patient awareness might have contributed to this apparent rise. A previous Ghanaian study showed that, while IBD was uncommon and diagnosis and commencement of treatment were often delayed, many patients were initially treated for infective colitis. This apparent rise in incidence may also reflect the increasing availability of diagnostic tools, such as flexible endoscopes, and the pathological expertise to appropriately interpret biopsies and bowel resection specimens.

Given the current scenario of few case reports, lack of gastroenterology clinics and a dearth of IBD registries or population-based surveys, it is impossible to estimate the prevalence of IBD in SSA. However, given the multiplicity of reports, it would be inaccurate to conclude that IBD is rare in this subregion. Quite possibly, diagnoses are often missed and hence it is quite conceivable that there is appreciable under-reporting, a lack of dedicated registries, inadequate facilities and a shortage of specialised health professionals all contribute to this epidemiological opacity.

Conclusions

The true burden of IBD in SSA remains unknown. Under-diagnosis, under-reporting, a lack of dedicated registries, inadequate facilities and a shortage of specialised health professionals all contribute to this epidemiological opacity. To begin to address these deficiencies, appropriate education of medical practitioners needs to start in earnest.

Declaration. None.

Acknowledgements. None.
Author contributions. GW and MS performed the literature search and the systematic review. All authors contributed to writing and editing of the manuscript.

Funding. None.

Conflicts of interest. None.


Accepted 20 August 2020.